KEYTRUDA has failed to receive a pharmaceutical Benefits Scheme (PBS) listing due to concerns from the PBAC around the incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY).
The PBAC said the submission from the sponsor's seven-year time horizon underestimated the ICER adding that if the criterion for treatment eligibility was changed from tumour proportion score (TPS) 50% to include all of the PD-L1 positive population (TPS 1%), the ICER would increase substantially, and would be unacceptably high.
Potential costs to the taxpayer would range from $100m to $200m over five years, the PBAC said.
Visit pbs.gov.au for more detail.
The above article was sent to subscribers in Pharmacy Daily's issue from 27 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Mar 17
